Halozyme Therapeutics, Inc. (NASDAQ:HALO) headquartered in San Diego, will host a conference call for the investment community to discuss the 3Q20 earnings result on 2nd November 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.halozyme.com
Earnings Expectation
Halozyme Therapeutics, Inc. is set to announce third quarter earning results on Monday 2nd November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, HALO to report 3Q20 income of $ 0.19 per share. For the full year, analysts anticipate top line of $ 235.94 million, while looking forward to income of $ 0.69 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 230.00 million ~ $ 245.00 million, where as bottomline are predicted in a range of $ 0.60 ~ $ 0.75 per share
Click Here For More Historical Outlooks Of Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The companys products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
